Nektar Therapeutics to Participate in Two Investor Conferences in March
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).
The TD Cowen presentation is webcast on Wednesday, March 4, 2026 at 9:10 a.m. ET with a replay available for 30 days; one-on-one meetings at Jefferies are available by request.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NKTR fell 7.06% while close biotech peers showed mixed, mostly modest moves (e.g., SANA +3.42%, ABUS +1.59%, SYRE -1.63%). No peers appeared in the momentum scanner, supporting this as a stock-specific move rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Research collaboration | Positive | +3.5% | Collaboration with UCSF to study NKTR-0165 in multiple sclerosis models. |
| Feb 13 | Offering closed | Positive | +0.5% | Closing of $460M public offering with underwriters’ option fully exercised. |
| Feb 11 | Offering priced | Positive | +18.5% | Pricing of upsized $400M public offering to fund rezpegaldesleukin Phase 3. |
| Feb 10 | Proposed offering | Positive | +51.1% | Announcement of proposed $300M public offering under effective S-3ASR shelf. |
| Feb 10 | Clinical data update | Positive | +51.1% | REZOLVE-AD Phase 2b data showing durable efficacy and favorable safety. |
Recent news, including offerings and positive clinical data, has generally coincided with positive 24-hour price reactions.
Over recent months, Nektar reported positive Phase 2b REZOLVE‑AD data, multiple equity offerings, a liquidity update, and a new NKTR‑0165 research collaboration. These events, often tied to rezpegaldesleukin’s advancement toward Phase 3 and capital raises, saw 24-hour moves up to 51.07%. Today’s conference-participation news fits an investor-relations cadence rather than a major clinical, financing, or partnership catalyst, contrasting with earlier price-moving announcements.
Market Pulse Summary
This announcement focuses on Nektar’s participation in March investor conferences, offering further visibility following recent REZOLVE‑AD Phase 2b data, sizeable equity offerings, and a new NKTR‑0165 collaboration. Investors may monitor how management frames Phase 3 plans, capital deployment from recent raises, and the broader pipeline narrative. Key items to watch include updates consistent with prior 8‑K and 424B5 disclosures and any refined timelines around rezpegaldesleukin’s Phase 3 program.
AI-generated analysis. Not financial advice.
- TD Cowen 46th Annual Health Care Conference in
Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here - 2026 Jefferies Biotech on the Beach Summit in
Miami – March 9-11, 2026 – company management to be available for one-on-one meetings
The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco,
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march-302696266.html
SOURCE Nektar Therapeutics
FAQ
When will Nektar Therapeutics (NKTR) present at the TD Cowen conference in March 2026?
How can investors watch Nektar Therapeutics (NKTR) webcast from the TD Cowen 46th Annual Health Care Conference?
What are the dates for Nektar Therapeutics (NKTR) at the 2026 Jefferies Biotech on the Beach Summit?
How can investors request a one-on-one meeting with Nektar (NKTR) at the March 2026 conferences?
Will there be a replay of Nektar's (NKTR) TD Cowen presentation and for how long will it be available?
Where can I find Nektar Therapeutics (NKTR) presentation materials and the webcast link for March 2026 events?
